



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/553,969	04/21/2000	Donald G. Wallace	17067-002040	6560

44183 7590 04/30/2009  
BAXTER HEALTHCARE CORPORATION  
ONE BAXTER PARKWAY  
MAIL STOP DF2-2E  
DEERFIELD, IL 60015

EXAMINER
----------

CHANNAVAJJALA, LAKSHMI SARADA

ART UNIT	PAPER NUMBER
----------	--------------

1611

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

04/30/2009

ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

elizabeth\_eich@baxter.com

<b>Office Action Summary</b>	<b>Application No.</b> 09/553,969	<b>Applicant(s)</b> WALLACE ET AL.	
	<b>Examiner</b> Lakshmi S. Channavajjala	<b>Art Unit</b> 1611	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 2-9-09.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1, 19, 21, 24-27, 29-32 and 34-36 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1, 19, 21, 24-27, 29, 31-32 and 34-36 is/are rejected.
- 7) ☐ Claim(s) 30 and 36 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

Receipt of response dated 6-12-08 and IDS dated 8-6-08 is acknowledged.

Claims 2-18, 20, 22-23, 28 and 33 have been canceled. Claims 1, 19, 21, 24-27, 29-32 and 34-36 are pending in the instant application.

#### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2-9-09 has been entered.

In response to the amendment to claim 1, limiting the claim to a protein, the following rejection has been withdrawn:

**Claims 1, 19-21, 23-26 and 35 are rejected under 35 U.S.C. 102(b) as being anticipated by US 4,124,705 to Rothman et al.**

**Claims 28-33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rothman et al as applied to claims 1, 19-21, 23-24 and 34 above, and further in view of US 4482386 to Wittwer and US 6,129,761 to Hubbell.**

**Claim 27 is rejected under 35 U.S.C. 103(a) as being unpatentable over Rothman et al in view of US 4,515,637 to Cioca.**

In light of the amendment, the following is a new rejection:

Claim 30 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

Instant claim 30 is dependent from claim 1, which is limited to an aqueous colloid being a protein. Instant claim now recites that the aqueous colloid is a polysaccharide, which contradicts claim 1.

Claim 36 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 31. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

Claim 36 recites the same features as the dependent claim 31, which incorporates all the limitations of claim 1 and also the additional limitation of a non-biological polymer.

***Claim Rejections - 35 USC § 103***

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

**Claims 1, 19, 21, 24, 29 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,482,386 to Wittwer et al (Wittwer).**

Art Unit: 1611

Wittwer et al teach conditioned water-swellaable hydrocolloids for use in mechanical forming processes such as processes such as die molding or injection molding in preparing shaped articles (abstract, col. 10 and col. 2, L 66 through col. 3, L 13). Wittwer teaches a number of polymers such as protein or non-biological polymers for preparing swellaable hydrocolloids including gelatin (col. 2, L 37-57). Example in col. 4 describes the preparation of gelating preparation, where in gelatin is conditioned or hydrated to 15% water content and the gelating granules. Further, Wittwer teaches that gelatin is in a granulated form with a mean particle diameter of 0.2 to 4 mm. (claim 6). With respect to the degradation claimed, the property of degradation is associated with gelatin. Wittwer does not teach the hydrocolloid in an applicator but suggests that the granulated gelatin is coupled with a molding unit such as an injection molding machine and therefore the claimed hydrogel being in an applicator with an extrusion orifice so as to be able to inject gelatin hydrocolloid would have been within the scope of a skilled artisan. Even though Wittwer fails to exemplify other swellaable polymers, it would have been obvious for a skilled artisan to choose a biological polymer such as protein or a non-biological polymer or a synthetic polymer to prepare swellaable hydrocolloids because Wittwer suggests that the process of preparing a swellaable hydrocolloids of predetermined water content, that are suitable for preparing moldable or shaped articles can also be prepared with synthetic polymers.

### ***Response to Arguments***

Applicant's arguments filed 2-9-09 have been fully considered but they are not persuasive.

Art Unit: 1611

It is argued that Wittwer describes a water-swellaable hydrocolloid, varying water swellaability with certain limits. It is argued that the absorption isotherm (fig. 1) shows water content that is 0.0 to 0.5 kg water per kg gelatin. It is argued that Wittwer does not even remotely contemplate the presently claimed equilibrium swells. As indicated in the instant application at, for example, page 18 lines 17-28, the term "equilibrium swell" can be defined as the percent swell at equilibrium, and the term "percent swell" can be defined as the dry weight subtracted from the wet weight, divided by the dry weight and multiplied by 100. According to this construction, Wittwer's maximum water content of about 0.5 involves a dry weight of 1.0kg and a wet weight of 1.5kg. Hence, Wittwer's resulting maximum percentage is  $((1.5-1)/1)*(100)= 50\%$ . Wittwer's 50% value relates to water content, but Wittwer does not mention equilibrium swell value ranges at all. Thus, it is argued that although Wittwer may discuss water content or varying the water swellaability, Wittwer does not teach or suggest equilibrium swells from 400% to 5000% as presently claimed. Hence, it is argued that the artisan would not be able to produce gelatin hydrocolloid gels with the desired amount of water and obtain an even distribution of water within the granules.

Applicants' arguments are not persuasive because Wittwer's disclosure is concerned with water-swellaable hydrocolloid and particularly, the product applied for injection molding in a swellaable state. Accordingly, applicants' arguments without any evidence to contrary, that the particles of Wittwer are not swollen are moot. The argument regarding free aqueous phase and swellaability is not persuasive because Wittwer only teaches gels for injection molding and not the addition of any suspensions

Art Unit: 1611

or carriers for such utility. Additionally, Wittwer suggests varying water swellability (col. 2, l 57-60) and also suggests obtaining particles with higher water content (col. 3, L 11). Wittwer suggests that to produce shaped articles with swellable hydrocolloids, the materials need to be plasticized and that plasticity of such water swellable colloids is a function of temperature (col. 1). Wittwer also states that swellability is also a function of the granularity and specific surface of the material and further suggests optimizing conditions of swellability so as to avoid degradation of the hydrocolloid. Wittwer is directed to solving the same problem as that of the instant invention i.e., obtain equilibrium swell, avoid rapid degradation, and maintain the water content. Thus, a skilled artisan would have been readily able to determine the conditions such as temperature, granularity, type of polymer, nature of crosslinking etc., in obtaining a hydrocolloid polymer with a predetermined amount of water, swellability and the degradation. Particularly, Wittwer suggests methods of obtaining higher quantities of water in the hydrocolloid and yet feel superficially dry such that they do not stick together (col. 3, L 1-10). The argument regarding fig. 1 is not persuasive because the teachings of the prior art are not limited to figures and examples and should be considered as a whole. One skilled in the art would be able to optimize the conditions so as to produce a hydrocolloid with desired amount of water (see claim 1 of Wittwer), even distribution of water within the granules, swellability and plasticity such that the final polymer does not degrade rapidly. For the argument regarding in vivo degradation, mere arguments without any evidence to show that the gelatin hydrocolloid gels do not degrade at the claimed rate are not persuasive.

**Claims 25-27 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4482386 to Wittwer as applied to claims 1, 19, 21, 24, 29, 31, 32, 34 and 36 above, and further in view of US 4,124,705 to Rothman et al and US 4,515,637 to Cioca.**

Wittwer teaches gelatin or synthetic polymers that swellable and also suitable for injection molding to prepare shaped articles. Wittwer teaches natural and synthetic polymers are suitable for the preparation of injectable hydrocolloids, but fails to teach an active agent (claim 25) such as a clotting agent (claim 26) or thrombin.

Rothman et al (hereafter Rothman) discloses an agent for intravascular administration consisting of a suspension of minute particles of a polysaccharide that is blocks the finer blood vessels (abstract, lines bridging col. 1-2 and paragraph bridging col. 11-col. 12). The polysaccharide of Rothman is biodegradable and resorbable because Rothman describes that the hydrophilic swellable particles are broken down by alpha-amylase in the blood plasma (col. 2, l 4-16) and further, according to the instant claim 35, the ability to be resorbable is inherent to the polysaccharide of Rothman. Similarly, the ability to swell is a property inherent to the polysaccharides described by Rothman. Rothman teaches a size range of 0.1 to 300 microns (col. 5, L 18-36), which overlaps with the claimed range of 0.01 mm to 5 mm (10 microns-5000 microns). Rothman further describes that the polymeric gel particles are produced by disintegrating the larger pieces of gel, which reads on fragmented gel claimed in the instant (col. 8, L 3-14). With respect to the limitations of "single phase" and



Art Unit: 1611

"substantially free from a free aqueous phase", Rothman does not teach including any other substance or component in the polysaccharide suspension other than for the formation of the gel or the ability to form a gel, and also states that the gels contain more than 50% by weight water but less than 98% water (col. 4, L 58-70), which implies that the gels do not contain any free water. Rothman discloses that the particulate suspension is injected intravascularly (col. 8, L 31-48), in conjunction with a therapeutic (col. 9, L 25-34) or a diagnostic agent (col. 8, L 49 through col. 9, L 24). Further the particulate suspension containing polysaccharide particles (of Rothman) read on a single phase aqueous colloid and are swellable upon administration and hence the presence of aqueous solution (for suspending the particles) and hence read on the claimed "free from a free aqueous phase". The therapeutic or diagnostic agents of Rothman read on instant claim 25 and particularly mention coagulation factors of claim 26 (col. 9, line 28-30). Rothman fails to teach the specific clotting agent, thrombin of claim 27, but teaches inclusion of clotting agents in the swellable gels for affecting coagulation.

Cioca teaches thrombin as an effective clotting factor for stoppage of bleeding locally (col. 2). Therefore, it would have been obvious for one of an ordinary skill in the art at the time of the instant invention was made to use swellable hydrocolloids of Wittwer containing gelatin polymer for delivering active agents such as coagulating factors to the desired site because Rothman suggests swellable hydrogels for delivering therapeutic agents such as coagulating agents. Further, it would have been obvious for

Art Unit: 1611

a skilled artisan to include thrombin as a coagulation factor in the hydrogel composition of Wittwer with an expectation of achieving the desired clotting or coagulation.

***Response to Arguments***

Applicants' arguments of 2-9-09 are not persuasive. It is argued that neither Rothman nor Cioca teach the claimed equilibrium swell and hence do not remedy the deficiencies of Wittwer. However, the arguments are not persuasive because the arguments regarding swelling have been addressed above. Rothman and Cioca have been cited for the motivation to include an active agent in the product of Wittwer.

**Claims 31-32 and 35-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4482386 to Wittwer as applied to claims 1, 19, 21, 24, 29, 31, 32, 34 and 36 above, and further in view of US 4,124,705 to Rothman et al and US 6,129,761 to Hubbell OR Alternatively, Claims 31-32 and 35-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4482386 to Wittwer as applied to claims 1, 19, 21, 24, 29, 31, 32, 34 and 36 above, and further in view of US 6,129,761 to Hubbell .**

Wittwer teaches gelatin or synthetic polymers that swellable and also suitable for injection molding to prepare shaped articles. Wittwer teaches natural and synthetic polymers are suitable for the preparation of injectable hydrocolloids, but fails to teach the combination with gelatin or other polymers, of instant claims.

Rothman, discussed above, teach polysaccharide swellable gels in combination with active agents or hydrocolloids comprising combinations of swellable polymers.

Art Unit: 1611

Hubbell teaches injectable hydrogel compositions useful for delivering cells or other bioactive agents via injection and thus provide engraftment and a 3-D template for new cell growth, custom molding of implants as well as implantation of tissues (abstract and col. 5, L 5-23) . The polymers of Hubbell include biodegradable, biocompatible hydrogels such as polylactides, polyanhydrides, polysaccharides and natural polymers such as gelatin, collagen, fibrin etc (col. 7-8), all of which described in the instant. Hubbell also teaches combination or mixtures of polymers (col. 8, L 63 –col. 9, L 12). It would have been obvious for one of an ordinary skill in the art at the time of the instant invention was made to combine other synthetic and natural swellable polymers of Rothman or Hubbell with the polysaccharide swellable polymers of Wittwer for administration because Wittwer suggests that protein as well synthetic polymers are suitable for preparing injection moldable articles, Rothman suggests polysaccharides and Hubbell suggests several swellable hydrogel polymers (both natural polymers such as gelatin and synthetic polymers) as well as their combinations for administering active agents to the localized or for tissue remodeling or preparing shaped moldable articles. Accordingly, a skilled artisan would have expected to be able to administer active agents or promote tissue engraftment with individual as well as mixtures of hydrogel polymers.

No claims are allowed.

Art Unit: 1611

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lakshmi S. Channavajjala whose telephone number is 571-272-0591. The examiner can normally be reached on 9.00 AM -5.30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sharmila G. Landau can be reached on 571-272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Lakshmi S Channavajjala/  
Primary Examiner,  
Art Unit 1611  
April 27, 2009